ALRN - Aileron Therapeutics launches ALRN-6924 trial in patients with advanced non-small cell lung cancer

Aileron Therapeutics (ALRN) perks up 5% after initiating a randomized, placebo-controlled clinical trial in the U.S. and in Europe of ALRN-6924 as a chemoprotective agent to treat patients with non-small cell lung cancer ((NSCLC)) undergoing chemotherapy.The company plans to enroll 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors in this Phase 1b trial.Primary endpoints are the proportion of treatment cycles free of severe hematological and other toxicities.An additional primary endpoint is the proportion of completed treatment cycles without chemotherapy dose reduction or without the use of growth factors or transfusions.Other endpoints include the proportion of patients with Grade 3/4 treatment-emergent adverse events, quality of life, overall response rate, and progression-free survival. Aileron anticipates reporting first interim safety data in Q4 2021 and full results in mid-2022.

For further details see:

Aileron Therapeutics launches ALRN-6924 trial in patients with advanced non-small cell lung cancer